Tesamorelin 20mg

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary to release its own growth hormone, achieving FDA-approved clinical efficacy for HIV-associated lipodystrophy with 15-20% visceral adipose tissue (VAT) reduction over 26 weeks—preferentially targeting dangerous abdominal fat while preserving subcutaneous fat and lean muscle mass, a metabolic selectivity unique among weight loss therapies.

The physiologic mechanism (pulsatile GH stimulation) avoids the feedback suppression and side effects of direct HGH therapy while raising IGF-1 levels 30-50%, supporting muscle preservation, bone density, collagen synthesis, and metabolic health. Clinical research demonstrates 37% hepatic steatosis reduction alongside VAT loss, making it valuable for fatty liver disease progression prevention. Unlike appetite suppressants causing global weight loss, Tesamorelin selectively mobilizes visceral fat through metabolic reprrogramming, with benefits persisting weeks after discontinuation. For individuals with dangerous abdominal obesity, metabolic syndrome, or fatty liver disease, Tesamorelin offers pharmaceutical-grade visceral fat targeting with lean preservation.